– PRECIPHOS –
A technology to diagnose and prognose more accurately and faster than today
– About us –
A FAMILY COMPANY
AT THE SERVICE OF HEALTH
The two scientific founders, Bernard Ludwig and Pascal Pflimlin, are driven by the belief that healthcare systems will not be able to continue providing the level of care required by patients due to insufficient funding.
A Scientific & Entrepreneurial Synergy
Convinced that the use of recent technologies can ensure high- quality care at a lower cost, they met with the medical community in Germany, France, and Switzerland. Together with the doctors, they conducted a detailed review of emerging technologies in Switzerland, Germany, France, Spain, and the USA.
They chose a technology from the Swiss Federal Institute of Technology in Zurich (ETHZ), which is capable of bringing breakthrough progress in the fields of medical diagnosis and prognosis.
They were then joined by the third co-founder, Jacques Neirynck, who brings his experience as an entrepreneur and business developer.
The company was founded in 2018 and has completed several fundraising rounds totaling €1.910 million, including €0.848 million in equity.
To date, the shareholders who have joined them are mostly industrial families confident in the company’s future, as well as known figures from the entrepreneurial and scientific worlds.
The choice fell on a technology from the Swiss Federal Institute of Technology in Zurich capable of bringing breakthrough advances in the field of medical diagnosis and prognosis.
A proprietary miniaturized immunological analysis platform called FoRe provides medical professionals with a set of convergent measurements enabling them to establish a diagnosis within the timeframes imposed by the rapid progression of the infection.
– Services –
Challenge & Value Proposition
Reducing healthcare costs by reducing diagnostic time and promoting precision medicine, starting with pediatric applications.
Reduction of infant mortality
quickness
FoRe provides quantified results within 30 minutes from a single drop of blood.
VERSATILITY
Portable, user-friendly and robust bio-analytical device for medical diagnostics and clinical research.
AFFORDABLE
– Who we are –
About PRECIPHOS
Blanck
Blanck
Blanck
Blanck
Our Ambition
Our Solution
A proprietary miniaturized immunological analysis platform called FoRe (Forward phase Reverse phase) provides medical professionals with a set of convergent measurements enabling them to establish a diagnosis within the timeframes imposed by the rapid progression of the infection.
Blanck
Blanck
Development opportunities
- The laboratory animal testing market
- The cardiovascular market
- The oncology and atherosclerosis market
- The veterinary market
- The clinical research market
High-performance, rapid diagnostics accessible to all thanks to FoRe Technology
Trusted Experts
Meet Our Team
Bernard Ludwig
CChem. | M.R.S.C.
CEO
Pascal Pflimlin
Senior Scientist
CTO
Jacques Neirynck
Co-founder & Chairman of the Strategic Board
Nicolas Ludwig
Chief Financial Officer
CFO
Vincent Pangon
Head of System Design & Compliance
Nathalie Satta Poschung
Chief Medical Development Officer – CMDO
– Our Partners –
They Support Our Project
– Get a call –
Don’t Hesitate To Contact With Us
Do You Have Any Questions?
For information and documentation relating to our products or for a specific request, do not hesitate to contact our team
: 8 place de l’hôpital – 67000 Strasbourg
Please Fill Up The Form
To Contact With Us
PRECIPHOS
Preciphos develop and market a multiplex, portable, user-friendly and cost-effective analytical device, based on a patented miniaturized immunological technology.
Contact
8 place de l'Hôpital
67000 Strasbourg - France -
